BUZZ-Steel Dynamics stock falls as quarterly profit misses expectations
路透社2026/10/19 21:01October 19 - ** Steel Dynamics Inc. (STLD.O) shares fell 7% in after-hours trading, to $228
** Despite strong steel prices and record shipment volumes, the company's recycling business profit decline, aluminum operations startup losses, and higher raw material costs continue to exert downward pressure
** For the third quarter, the company reported earnings per share of $5.26, missing Wall Street's expected $5.41 — data compiled by LSEG
** "U.S. steel import volumes remain well below historical and year-ago levels," said Chief Executive Mark Millett
** The company reported quarterly revenue of $6.51 billion, higher than the expected $6.43 billion
**As of the previous market close, the stock was up 44.5% year-to-date
(To facilitate non-English speakers, Reuters has automatically translated its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation. It is provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Dollar Index falls to near 101.50 amid Fed rate pause odds, easing safe-haven demand

Utexo Mint open beta: Get early access to USD₮ on the bitcoin blockchain

"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%
Traders weighed the impact of Saudi attack risks and sharply reduced demand, causing oil prices to fall more than 2%.

JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential
Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.